Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study

被引：0
作者：
Lucheng ZHU
Changlin Zou
Zhanchun Zhang
Jianfang Wang
Li Yang
Chuangzhou Rao
Zhiping Yang
Jiafeng Liang
Bing Xia
M. A. Shenglin
机构：
[1] Affiliated Hangzhou Cancer Hospital,Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province
[2] Zhejiang University School of Medicine,Department of Radiotherapy
[3] The First Affiliated Hospital of Wenzhou Medical University,Department of Radiotherapy
[4] Ningbo Medical Center Lihuili Hospital,Department of Radiotherapy, Shaoxing People’s Hospital (Shaoxing Hospital
[5] Zhejiang University School of Medicine),Department of Pulmonary & Critical Care Medicine, Shulan (Hangzhou) Hospital
[6] Affiliated to Zhejiang Shuren University Shulan International Medical college,Department of Radiotherapy & Chemotherapy,Hwa Mei Hospital
[7] University of Chinese Academy of Sciences,Department of Oncology, Affiliated Hospital of Jiaxing University
[8] The First Hospital of Jiaxing,Department of Oncology
[9] Jiande Second People’s Hospital,Department of Cancer Medical Center
[10] Affiliated Xiaoshan Hospital,undefined
[11] Hangzhou Normal University,undefined
来源：
BMC Cancer | / 21卷
关键词：
Almonertinib; EGFR-TKI; Radiotherapy; Locally advanced NSCLC; Radiation pneumonitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Radiation Pneumonitis Following Twice-daily Radiotherapy with Concurrent Carboplatin and Paclitaxel in Patients with Stage III Non-small-cell Lung Cancer
    Kobayashi, Hiroki
    Uno, Takashi
    Isobe, Koichi
    Ueno, Naoyuki
    Watanabe, Miho
    Harada, Rintaro
    Takiguchi, Yuichi
    Tatsumi, Koichiro
    Ito, Hisao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (05) : 464 - 469
  • [22] Surgery in stage III non-small-cell lung cancer
    Eberhardt, Wilfried E. E.
    Stamatis, Georgios
    Stuschke, Martin
    LANCET, 2009, 374 (9687) : 359 - 360
  • [23] Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer
    Kaderbhai, C-G
    Coudert, B.
    Bertaut, A.
    Adnet, J.
    Favier, L.
    Lagrange, A.
    Peignaux-Casasnovas, K.
    Mettey, L.
    Tharin, Z.
    Foucher, P.
    Martin, E.
    CANCER RADIOTHERAPIE, 2020, 24 (04): : 279 - 287
  • [24] Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer
    Cheema, P. K.
    Rothenstein, J.
    Melosky, B.
    Brade, A.
    Hirsh, V.
    CURRENT ONCOLOGY, 2019, 26 (01) : 37 - 42
  • [25] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [26] Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
    Inoue, Akira
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2020, 96 (07): : 266 - 272
  • [27] Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: A case report
    Yeo, Seung-Gu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (02) : 769 - 772
  • [28] PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer
    N. Zhang
    Y. Gao
    Z. Zeng
    Y. Luo
    X. Jiang
    J. Zhang
    J. Li
    J. Zhang
    Y. Gong
    C. Xie
    Clinical and Translational Oncology, 2021, 23 : 1827 - 1837
  • [29] Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study
    Kim, Dong-Wan
    Cho, Byoung Chul
    Pachipala, Krishna
    Kim, Sang-We
    Wang, Chih-Liang
    Chang, Gee -Chen
    Ahn, Myung-Ju
    Alvarez, Rosa
    Chiu, Chao-Hua
    Trigo, Jose
    Estival, Anna
    Karam, Sana D.
    O'Brien, Cathy
    Gowda, Hema
    Jiang, Haiyi
    Bauman, Julie E.
    LUNG CANCER, 2024, 190
  • [30] PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer
    Zhang, N.
    Gao, Y.
    Zeng, Z.
    Luo, Y.
    Jiang, X.
    Zhang, J.
    Li, J.
    Gong, Y.
    Xie, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (09) : 1827 - 1837
12345